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Inhibition by triacsins and troglitazone of long chain
fatty acid incorporation into cellular lipids suggests the
existence of inhibitor-sensitive and -resistant acyl-CoA
synthetases (ACS, EC 6.2.1.3) that are linked to specific
metabolic pathways. In order to test this hypothesis, we
cloned and purified rat ACS1, ACS4, and ACS5, the iso-
forms present in liver and fat cells, expressed the iso-
forms as ACS-Flag fusion proteins in Escherichia coli,
and purified them by Flag affinity chromatography. The
Flag epitope at the C terminus did not alter the kinetic
properties of the enzyme. Purified ACS1-, 4-, and 5-Flag
isoforms differed in their apparent Km values for ATP,
thermolability, pH optima, requirement for Triton
X-100, and sensitivity to N-ethylmaleimide and phenyl-
glyoxal. The ACS inhibitor triacsin C strongly inhibited
ACS1 and ACS4, but not ACS5. The thiazolidinedione
(TZD) insulin-sensitizing drugs and peroxisome prolif-
erator-activated receptor g (PPARg) ligands, troglita-
zone, rosiglitazone, and pioglitazone, strongly and spe-
cifically inhibited only ACS4, with an IC50 of less than
1.5 mM. Troglitazone exhibited a mixed type inhibition of
ACS4. a-Tocopherol, whose ring structure forms the
non-TZD portion of troglitazone, did not inhibit ACS4,
indicating that the thiazolidine-2,4-dione moiety is the
critical component for inhibition. A non-TZD PPARg
ligand, GW1929, which is 7-fold more potent than rosigli-
tazone, inhibited ACS1 and ACS4 poorly with an IC50 of
greater than 50 mM, more than 100-fold higher than was
required for rosiglitazone, thereby demonstrating the
specificity of TZD inhibition. Further, the PPARa li-
gands, clofibrate and GW4647, and various xenobiotic
carboxylic acids known to be incorporated into complex
lipids had no effect on ACS1, -4, or -5. These results,
together with previous data showing that triacsin C and
troglitazone strongly inhibit triacylglycerol synthesis
compared with other metabolic pathways, suggest that
ACS1 and ACS4 catalyze the synthesis of acyl-CoAs used
for triacylglycerol synthesis and that lack of inhibition
of a metabolic pathway by triacsin C does not prove lack
of acyl-CoA involvement. The results further suggest the
possibility that the insulin-sensitizing effects of the thia-
zolidinedione drugs might be achieved, in part, through
direct interaction with ACS4 in a PPARg-independent
manner.
Acyl-CoA synthetase (ACS,1 EC 6.2.1.3) catalyzes the liga-
tion of long chain fatty acids with coenzyme A (CoA) to produce
long chain acyl-CoAs (1). The resulting acyl-CoAs can be fur-
ther metabolized in pathways of b-oxidation, glycerolipid syn-
thesis, cholesteryl ester (CE) synthesis, desaturation, elonga-
tion, and protein acylation and can serve as signaling
molecules (2–4). Although ACS was first believed to be a con-
stitutive enzyme because the activity in liver was not altered by
changes in nutritional status or hormonal stimuli (5–9), the
cloning of ACS1 from rat liver in 1990 disclosed that hepatic
ACS1 mRNA expression is sensitively regulated by fasting and
refeeding as well as by specific nutrients provided as the energy
source (10). Later, four additional rat ACS isoforms from dif-
ferent genes were cloned that differed in tissue distribution of
their mRNA expression and in substrate preference (11–14). Of
these, ACS2 and ACS3 mRNAs are abundantly expressed in
brain, but are not detected in liver (13, 14). The mRNAs of
ACS4 and ACS5 are highly expressed in steroidogenic tissues
and in intestine, respectively, and are also present in liver (11,
12). ACS1 and ACS5 have a broad substrate specificity for
saturated fatty acids of 12–18 carbon atoms and unsaturated
fatty acids of 16–20 carbon atoms. In contrast, ACS4 has a
marked preference for arachidonic acid and eicosapentaenoic
acid. The presence of three ACS isoforms in liver suggests that
liver ACS activity does not change with physiological alter-
ations (5–9) because the different ACS isoenzymes compensate
for each other.
All ACS isoenzymes are members of the luciferase superfam-
ily and have a common structure that consists of an N termi-
nus, two luciferase-like regions, a linker connecting the two
luciferase-like regions, and a C terminus. A highly conserved
AMP-binding site and a predicted fatty acid binding site are
located in the first and the second luciferase-like regions, re-
spectively (10–14). ACS1, ACS2, and ACS5 are structurally
similar, with more than 60% amino acid identity (11). ACS3
and ACS4 form a second subgroup with ;30% homology to
ACS1 and 68% identity to each other (12). Despite their high
degree of homology, the expression of ACS1 and ACS5 mRNA is
regulated independently. In liver, both ACS1 and ACS5
mRNAs are increased by high sucrose refeeding whereas high
fat refeeding increases only ACS1 mRNA. ACS5 is the sole
member of the ACS family whose mRNA decreases with fasting
(11). In 3T3-L1 cells, ACS1 mRNA is detected only after adi-
pocyte differentiation, whereas ACS5 mRNA is consistently
expressed independent of differentiation status (10, 11). In the
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adrenal, ACS4 expression increases with exposure to adreno-
corticotropic hormone and to arachidonate (15). These differ-
ences in regulation, tissue distribution, and substrate prefer-
ence suggest that each ACS isoform might function
independently in various tissues for different metabolic
purposes.
Use of two inhibitors of ACS has suggested the presence of
different acyl-CoA pools within cells, because these inhibitors
are effective in blocking only some of the metabolic pathways
that require long chain acyl-CoAs. For example, in human
fibroblasts, the fungal metabolite triacsin C almost completely
inhibits de novo synthesis of triacylglycerol and phospholipid
from glycerol, but does not prevent phospholipid synthesis via
reacylation of lysophospholipids with oleate or arachidonate
(16). Similar results are observed in rat hepatocytes in which
triacsin C blocks de novo synthesis of TAG 73%, but inhibits
[14C]oleate incorporation into phospholipid and CE, or metab-
olism via b-oxidation only 30–40% (17). In HepG2 cells, triac-
sin D inhibits oleate-induced TAG synthesis 80% without af-
fecting CE synthesis (18), and in rat primary hepatocytes,
troglitazone at 100 mM inhibits [14C]oleate incorporation into
TAG and oxidation products 50% and 20%, respectively,
whereas incorporation into phospholipid remains unaffected
(19). The sulfo-conjugate of troglitazone appeared to be the
likely inhibitory metabolite (19).
These differing effects of ACS inhibitors on metabolic end
products of acyl-CoA-dependent pathways suggest the presence
of inhibitor-sensitive and -resistant ACSs that are linked to
specific pathways. If so, ACS isoforms might play a critical role
in partitioning acyl-CoAs toward lipid synthesis versus oxida-
tion. In order to determine whether this hypothesis was cor-
rect, we needed to examine the effects of the ACS inhibitors on
each of the three ACS isoforms expressed in liver and fat cells.
To do this, we expressed ACS1, ACS4, and ACS5 as recombi-
nant ACS-Flag fusion proteins, and purified each ACS by Flag
antibody column chromatography.
EXPERIMENTAL PROCEDURES
Materials—RT-for-PCR kit and Advantage 2 PCR kit were pur-
chased from CLONTECH. Bacterial Flag expression kit including
pFlag-CTC vector, Flag M2 affinity column, and Flag peptides, amino-
phenylboronate, phenylglyoxal, N-ethylmaleimide, coenzyme A, ATP,
palmitate, xenobiotic carboxylic acids, and Triton X-100 were from
Sigma. HMS174(DE3) and pET21a(1) expression vector were from
Novagen. [9,10-3H]Palmitic acid was from PerkinElmer Life Sciences.
Triacsin C was from Biomol. The thiazolidinediones, GW1929 and
GW4647 were a gift from Dr. Steven Jacobs, GlaxoSmithKline.
Construction of Recombinant pACS-Flag Plasmids—cDNA was syn-
thesized from rat liver total RNA and used as a template for amplifi-
cation of the ACS open reading frames (CLONTECH, RT-for-PCR kit).
The primers for amplification of ACS1, ACS4, and ACS5 were designed
to include the entire open reading frames based on nucleotide sequences
obtained from the GenBanky data base (accession nos. D90109,
D85189, and AB012933 for ACS1, ACS4, and ACS5, respectively) and
specific restriction sites. The upper primer for ACS1 was 59-ACA-
GACTCGAGGAGGTCCATGAATTGTTCCGTA-39 (recognition site in-
dicated in boldface type) and the lower primer was 59-CCTCGGTAC-
CAATCTTGATGGTGGAGTACAG-39. The upper and lower primers for
ACS4 were 59-AAAAGCTTGCAAAGAGAATAAAGGCTAAGC-39 and
59-TTGCGTCGACTTTGCCCCCATACATC-39. The upper and lower
primers for ACS5 were 59-TATTCCTCGAGCTTTTTATTTTTAACT-
TCTTGTTTTC-39 and 59-CTTGGTACCCTCTTCGATGCTCATAGAG-
39. ACS amplification was performed by PCR with the designed primers
and Advantage®2 PCR kit (CLONTECH). The amplified ACS1 PCR
product was digested with XhoI and Acc65I and ligated into pFlag-CTC
vector (Sigma) digested with the same restriction enzymes. The ACS4
PCR product and the pFlag-CTC vector were digested with HindIII and
SalI and then ligated. To obtain ACS4 without the Flag sequence, a
primer was designed by adding a stop codon in the position just before
the Flag sequence. The upper primer used was the same as for ACS4-
Flag fusion protein, and the newly designed lower primer was 59-
ACAGTGTCGACTTATTTGCCCCCATACAT-39 (stop codon is under-
lined). The pFlag-ACS plasmid constructs contain a tac promoter, a
ribosome binding site, the entire coding region of each ACS isoforms,
and C-terminal Flag sequences with pBR322 origin. For ACS5, the
pET-Flag vector was used. The plasmid pET-Flag was constructed by
cloning the SphI (Klenow-filled)-NheI fragment from pET-21a(1) (No-
vagen) into pFlag-CTC (Sigma) digested with BamHI, treated with
Klenow, and then digested with NheI. In the pET-Flag vector, the tac
promoter region in pFlag-CTC was replaced with the T7 promoter
region from pET21a(1) (Novagen). ACS5 PCR products and pET-Flag
vector were digested with XhoI and Acc65I and then ligated. The
sequences of ACS-Flag fusion constructs were verified by the University
of North Carolina Automated Sequencing Facility.
Expression of Recombinant ACS1- and ACS4-Flag Proteins in Esch-
erichia coli—Recombinant ACS1-Flag, ACS4-Flag, and ACS4 were ex-
pressed in E. coli JM109 after induction with 1 mM IPTG at an A600 of
1.0. JM109 was grown in Terrific Broth (Life Technologies, Inc.) sup-
plemented with ampicillin (60 mg/ml) at 30 °C and shaken at 250 rpm.
After a 12-h induction, cells were harvested by centrifugation at 5,000
rpm for 10 min in a Sorvall HS-4 rotor. The cell pellet was resuspended
in 10 ml of 10 mM Tris (pH 7.4), 0.5 mM EDTA (TE) buffer. The
resuspended cells were incubated with 100 mg/ml lysozyme for 30 min
on ice and then sonicated with six 10-s bursts, each followed by a 10-s
rest on ice. Cellular debris was removed from the cell lysates by cen-
trifugation at 3,000 3 g for 10 min. Part of the supernatant was saved
(cell extract), and the remainder was layered over a 2-ml cushion of 55%
(w/w) sucrose topped with 0.5 ml of 5% (w/w) sucrose in TE buffer. After
centrifugation in a Beckman SW41 rotor at 35,000 rpm for 3 h, the
supernatant was removed (soluble fraction). The membrane band at the
interface was collected with a 19-gauge needle and syringe. Protein
concentrations were determined by the BCA method (Pierce) with bo-
vine serum albumin as the standard.
Purification of the Recombinant ACS1- and ACS4-Flag Proteins—
ACS1-Flag and ACS4-Flag were purified by Flag M2 column chroma-
tography. The Flag M2 antibody affinity matrix (1 ml) (Sigma) was
activated with 0.1 M glycine (pH 3.5), 50 mM Tris (pH 7.4), and 150 mM
NaCl (TBS) buffer. JM109 membrane fractions containing overex-
pressed ACS1-Flag or ACS4-Flag were solubilized in TBS containing
1% Triton X-100 and passed over the column four times. The column
was washed three times with 12 ml of TBS (pH 7.4), and then eluted
with five 1-ml aliquots of 100 mg/ml Flag peptide (Sigma) dissolved in
TBS buffer (pH 7.4). Eluates were run on a 10% polyacrylamide gel
containing 1% SDS and stained with Gel Code® blue stain reagent
(Pierce). ACS4 and ACS1 were purified to near homogeneity and mi-
grated as single bands. Compared with the cell extracts the activities of
purified proteins increased 19-fold for ACS1 and 10-fold for ACS4.
Expression and Purification of Recombinant ACS5-Flag Protein—
Unlike ACS1- or ACS4-Flag, ACS5-Flag protein could not be expressed
under the tac promoter in JM109 or DH5a. To express ACS5-Flag, we
used the pET-Flag vector because the T7 promoter regulates the ex-
pression of foreign proteins more tightly than does the tac promoter.
Overexpressed ACS5-Flag was present in the membrane fraction of
HMS174(DE3). ACS5-Flag was maximally expressed at 30 °C after a
12-h induction with 1 mM IPTG beginning at an A600 of 0.4 in
HMS174(DE3), which provides the T7 polymerase. Purification of ac-
tive ACS5-Flag was similar to that described for ACS1 and ACS4,
except that 0.1% Triton X-100 was required in the elution buffer that
contained 100 mg/ml Flag peptide. When Triton X-100 was omitted, only
inactive ACS was eluted. ACS5-Flag migrated as a single band on a 10%
polyacrylamide gel containing 1% SDS and stained with Gel Code® blue
stain reagent. Compared with the cell extracts, the activities of purified
proteins increased 29-fold for ACS5. The purification yield was rela-
tively low because excess protein applied to the column was eluted in
the flow-through fraction and during the washing procedure.
Assay for ACS Activity—The ACS assay contained 50 mM [3H]palmi-
tate in Triton X-100, 1 mM EDTA, 10 mM ATP, 250 mM CoA, 175 mM Tris
(pH 7.5), 8 mM MgCl2, and 5 mM dithiothreitol in a total of 200 ml (20,
21). The maximum concentration of Triton X-100 in the assay was
0.03% (0.5 mM). All comparisons of the recombinant ACS isoenzymes
employed identical concentrations of substrates and Triton X-100. The
reaction was initiated with 0.1 mg of protein for ACS1 and ACS4, and
0.5–1.0 mg of protein for ACS5. ACS activity was measured after a
5-min incubation at 37 °C, except for the inhibition kinetic studies,
which were only incubated for 1 min (20). Substrate concentrations and
time allowed measurement of initial rates. The specific activities of
recombinant ACS1-, ACS4-, and ACS5-Flag proteins from different
preparations were in the ranges of 939–1472, 1670–2200, and 98–166
nmol/min/mg, respectively. All the experiments were repeated three
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times, and virtually identical results were obtained from each
experiment.
RESULTS
Expression and Purification of Recombinant ACS-Flag Pro-
teins—Recombinant rat ACS1, ACS4, and ACS5 had previously
been purified by column chromatography (10–12). To obtain
purified ACS isoenzymes more efficiently, we designed plasmid
constructs to produce ACS proteins with Flag epitopes at their
C termini. After induction with IPTG, 10% of the ACS activity
was found in the soluble fraction. This soluble activity is sur-
prising because ACS4 is an integral membrane protein, which
remains associated with rat liver microsomes after washing
with 0.5 M KCl (data not shown). Nevertheless, soluble ACS4
(21%) was also obtained when ACS4 was overexpressed in
DH5a (12). ACS1- and ACS5-Flag were also overexpressed and
identified in the membrane fraction. Recombinant ACSs were
purified to near homogeneity by one-step Flag-antibody affinity
chromatography. To ensure that the Flag epitope did not alter
ACS function, we compared ACS activity in membrane frac-
tions from JM109 that overexpressed ACS4 or ACS4-Flag. The
kinetic constants for palmitic acid, CoA, and ATP were virtu-
ally identical, and the sensitivity to heating at 43 °C was sim-
ilar, indicating that the Flag epitope at the C terminus does not
alter the catalytic properties of ACS and supports the use of
ACS-Flag recombinant proteins for comparative study (data
not shown).
Characterization of ACS1, ACS4, and ACS5—To compare
the purified ACS isoenzymes, we studied the kinetics of the
three substrates required for ACS catalysis. The three ACS
isoenzymes had similar apparent Km values for CoA between
2.4 and 6.4 mM and for palmitic acid between 5.0 and 8.6 mM
(Table I). ACS4, on the other hand, had an apparent Km value
for ATP that was almost 20-fold lower than that of ACS1 or
ACS5 (34 mM versus 649 and 666 mM). To test sensitivity to
heating, ACS isoenzyme activities were measured after heating
at 43 °C for various times (Fig. 1). ACS1 was most stable to
heat with a half-life of about 10 min whereas ACS4 had a t1⁄2
shorter than 2 min, and ACS5 had a t1⁄2 of ;4 min. To find the
optimum pH for each ACS isoenzyme, MES was used as a
buffer for ACS reaction in the range of pH 6–7, Tris for pH 7–9,
and glycine for pH 9 and 9.5. ACS1 and ACS4 had broad pH
optima between pH 7.4 and 9.0, but the optima for ACS5 was
more narrow (pH 7.4–8.0) (data not shown). The three purified
ACS isoenzymes were differently affected by Triton X-100 (Fig.
2). ACS4 gradually lost activity at Triton X-100 concentrations
above 0.5 mM, the concentration normally used for assay,
whereas ACS1 maintained maximal activity up to 1.5 mM Tri-
ton X-100. In contrast, ACS5 activity dramatically increased at
Triton X-100 concentrations above 0.5 mM, and maintained
maximal activity at 3 mM. ACS5 remained highly active even at
10 mM Triton X-100 (data not shown).
Triacsin C Strongly Inhibited ACS1 and ACS4, but Did Not
Affect ACS5—Triacsin C, an alkenyl-N-hydroxytriazene fungal
metabolite, was reported to be a potent competitive inhibitor of
ACS (22, 23). Studies in fibroblasts, HepG2 cells, and rat hepa-
tocytes, however, suggest that triacsin C does not equally in-
hibit all the pathways in which acyl-CoAs are used. To test the
effects of triacsin C on the purified ACS isoenzymes, triacsin C
was added directly to the reaction mixture (Fig. 3). Triacsin C
selectively and strongly inhibited ACS1 and ACS4 in a dose-
dependent manner, but had little effect on ACS5. The IC50 for
ACS1 and ACS4 was 4–6 mM.
Thiazolidinediones Are Specific Inhibitors of ACS4—Thiazo-
lidinediones are oral antidiabetic drugs, generally believed to
act as insulin sensitizers through activation of PPARg (24–26).
Because the sulfo-conjugate of troglitazone was reported to
directly inhibit ACS activity in both microsomes and mitochon-
dria from rat liver (19), we tested purified recombinant ACS1,
ACS4, and ACS5 to determine which isoform was inhibited by
thiazolidinediones. Troglitazone at 1 mM decreased ACS4 activ-
ity 50%; with 10 mM troglitazone, the activity was almost com-
pletely blocked (Fig. 4A). In contrast, ACS1 and ACS5 activities
were unaffected by troglitazone at 10 mM. Because troglitazone
contains the ring structure of a-tocopherol linked to the thia-
zolidinedione moiety, we determined which part of the mole-
cule was critical for inhibition by testing the effect of a-tocoph-
erol itself and of other thiazolidinediones on each of the
purified ACS isoenzymes. a-Tocopherol had little effect on
three ACS isoforms (Fig. 4B). On the other hand, both piogli-
tazone and rosiglitazone, which contain the common thiazo-
TABLE I
Kinetic constants for ACS1, ACS4, and ACS5
Recombinant, purified enzymes were assayed as described under
“Experimental Procedures.” Substrate concentrations for these studies
were held to between 0.3 and 2.0 times the Km value (30).
Substrate ACS1 ACS4 ACS5
ATP
Km (mM) 649 34 666
Vmax (nmol/min/mg protein) 1012 1050 287
CoA
Km (mM) 6.4 4.1 2.4
Vmax (nmol/min/mg protein) 1072 2092 75
Palmitate
Km (mM) 5.0 5.4 8.6
Vmax (nmol/min/mg protein) 1695 2800 130 FIG. 1. ACS1-, ACS4-, and ACS5-Flag proteins differ in thermo-
lability. Purified ACS1-Flag (E) and ACS4-Flag (l) (each 4 mg/ml) and
ACS5-Flag (f) (40 mg/ml) were heated at 43 °C in TE buffer. Samples
containing 0.1 mg of protein were removed at the times indicated for
immediate assay at 37 °C. Initial activities were 873 for ACS1, 1491 for
ACS4, and 97 nmol/min/mg for ACS5.
FIG. 2. Triton X-100 activates ACS5. The activities of purified
ACS1-Flag (E) and ACS4-Flag (l) (each 0.1 mg) and ACS5-Flag (f) (1
mg) isoenzymes were measured in the presence of different concentra-
tions of Triton X-100. ACS activity at 0.5 mM Triton X-100, the concen-
tration regularly used in the assay, represents 100%. Activities with 0.5
mM Triton X-100 were 1340 for ACS1, 2220 for ACS4, and 100 nmol/
min/mg for ACS5.
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lidinedione group but lack the a-tocopherol moiety, showed
virtually the same effect as troglitazone on the three ACS
isoenzymes. At 10 mM both drugs inhibited ACS4 85–95%,
inhibited ACS5 less than 20%, and did not alter ACS1 activity
(Fig. 4, C and D). At concentrations up to 10 mM, troglitazone
had little effect on ACS5 activity, even after full activation by 3
mM Triton X-100 (data not shown). Of the thiazolidinediones,
rosiglitazone was the strongest inhibitor of ACS4. The IC50 was
0.5 mM for rosiglitazone and 1.5 mM for troglitazone and piogli-
tazone (Table II). These data indicate that the thiazolidine-2,4-
dione moiety is the critical moiety for ACS4 inhibition.
Troglitazone exhibited a mixed type inhibition of ACS4. With
respect to palmitate, the reciprocal plots intersected above the
1/palmitate axis (Fig. 5A) and the Ki was 0.1 mM as calculated
from the Km/vmax versus inhibitor replot (Fig. 5B). Since the 1/v
replot intersected with the Km/vmax replot near the y axis, we
can characterize the system as exhibiting linear non-competi-
tive inhibition. Linear mixed inhibition also arises when an
inhibitor binds at mutually exclusive sites. Therefore, we ex-
amined troglitazone inhibition kinetics of CoA and ATP, the
other two substrates of ACS4. Troglitazone exhibited partial
uncompetitive inhibition with respect to CoA (Fig. 5C). For
ATP, the reciprocal plots intersected below the 1/palmitate axis
(Fig. 5D), another linear mixed-type inhibition system.
Non-thiazolidinedione PPARg and PPARa Activators Do Not
Inhibit ACS4—N-(2-Benzoylphenyl)L-tyrosine (GW1929) is a
newly identified non-thiazolidinedione PPARg activator with a
high affinity for human PPARg (27). The glucose-lowering ef-
fect of GW1929 in rats is 100-fold more potent than that of
troglitazone (27). In contrast, however, GW1929 was a poor
inhibitor of ACS4 with an IC50 of 50 mM versus 1.5 mM for the
TZDs) (Table II). PPARa activators such as clofibric acids or
GW4647 up to 50 mM had no effect on ACS1, ACS4, or ACS5
(Table II) despite the ability of PPARa ligands to improve
insulin sensitivity and reduce adiposity (28). We also tested a
variety of xenobiotic carboxylic acids, which contain hydropho-
bic and carboxylic acid moieties, are known to be incorporated
into complex lipids, and either resemble natural fatty acids or
are aromatic derivatives of short chain fatty acids (29). The
long chain cyclopropane (bridged) analogue of oleic acid,
(6)-cis-9,10-methylene octadecanoic acid, inhibited ACS1 and
ACS4 activities 50% at 25 and 30–40 mM, respectively, but had
no effect on ACS5. Other xenobiotic carboxylic acids, 3-phe-
noxybenzoic acid, p-coumaric acid, ibuprofen, ferulic acid, and
firefly luciferin, at concentrations up to 50 mM had no effect on
three ACS isoenzymes.
N-Ethylmaleimide Strongly Inhibited ACS4 and Weakly In-
hibited ACS1, but Had No Effect on ACS5—To further charac-
terize the ACS isoenzymes, the effects of amino acid-reactive
compounds were investigated. Before assay, each purified ACS
isoenzyme was pre-incubated with various concentrations of
NEM, a sulfhydryl-reactive compound, for 10 min on ice (Fig.
6). NEM at 3 mM inhibited ACS4 and ACS1 activities 83% and
25%, respectively, but had no effect on ACS5, indicating that
amino acids containing a sulfhydryl group were more critical
FIG. 3. Triacsin C inhibits ACS1 and ACS4. Purified ACS1-Flag
(E) and ACS4-Flag (l) (each 0.1 mg) and ACS5-Flag (f) (0.5 mg) were
assayed for ACS activity in the presence of varying concentrations of
triacsin C dissolved in Me2SO (2.5% of final assay reaction). The values
are from an experiment that is representative of three independent
determinations. Activities in the absence of triacsin C were 763 for
ACS1, 1378 for ACS4, and 63 nmol/min/mg for ACS5.
FIG. 4. Thiazolidinediones inhibit ACS4. Purified ACS1-Flag (E)
and ACS4-Flag (l) (each 0.1 mg) and ACS5-Flag (f) (1 mg) were assayed
for ACS activity. Troglitazone, pioglitazone, rosiglitazone, and a-to-
copherol were dissolved in Me2SO (2.5% of final assay reaction). The
values shown are from an experiment that is representative of two
independent determinations. A, troglitazone; B, a-tocopherol; C, piogli-
tazone; D, rosiglitazone.
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for ACS4 catalysis compared with ACS1 or ACS5 (Fig. 5). After
a 10-min preincubation, the arginine-reactive compound, phe-
nylglyoxal, at 25 mM inhibited ACS1 38%, ACS4 78%, and
ACS5 65%, suggesting the importance to each isoform of an
arginine residue for catalysis (data not shown). m-Aminophe-
nylboronate (0–20 mM), a serine-reactive compound, however,
had little effect on ACS1, ACS4, and ACS5 (data not shown).
DISCUSSION
We focused on ACS1, ACS4, and ACS5 because these three
isoforms are present in liver, a tissue that metabolizes long
chain fatty acids via a variety of synthetic and degradative
pathways. To characterize ACS1, ACS4, and ACS5 and test the
effects of inhibitors, we purified each ACS isoform as a ACS-
Flag fusion protein after confirming that the Flag sequence at
the C terminus does not alter enzymatic kinetic properties. The
ACS5-Flag fusion protein was unique with regard to the con-
ditions required for its expression, purification, and full recov-
ery of activity. Although others have expressed ACS5 without
reported difficulty in DH5a with a vector containing the lac
promoter (11), our successful ACS5 expression required a vec-
tor containing the T7 promoter, suggesting that the ACS5
protein may be toxic to E. coli since the T7 promoter-driven
vector suppresses the expression of foreign proteins in unin-
duced states more completely. In addition, elution of active
ACS5-Flag from the Flag antibody column required the pres-
ence of 0.1% Triton X-100 in the elution buffer, whereas active
ACS1 and ACS4 could be eluted without adding detergent.
Furthermore, the loss of 50% of ACS5 activity, merely in the
process of obtaining bacterial membranes, suggests that deter-
gent might be helpful at every stage of preparation. Although
0.5 mM Triton X-100 is regularly used in the ACS assay, we
found that maximal activation of ACS5 demanded an ;6-fold
higher concentration of Triton X-100. Thus, optimal assay con-
ditions required the presence of ;500 Triton X-100 micelles/
molecule of ACS1 or ACS4, and about 3000 micelles/molecule of
ACS5. The critical micellar concentration of Triton X-100 is 0.3
mM, and, although it remains unclear why ACS5 requires such
a large number of Triton X-100 micelles, the detergent may be
essential to reconstitute or stabilize purified ACS5 or to relieve
product inhibition by palmitoyl-CoA. In order to be consistent
in our comparisons, we used identical concentration of Triton
X-100 (0.5 mM) and substrates to assay all recombinant ACS
isoenzymes.
The three purified ACS isoenzymes had similar apparent Km
values for CoA and palmitic acid. The apparent Km for palmitic
acid of ACS4 in this study is more than 10-fold lower than the
one reported previously (12), probably because the concentra-
tions of palmitic acid we used to study kinetics ranged from
0.33 to 2.0 of the Km, as recommended (30). ACS4 had approx-
imately a 20-fold higher affinity for ATP than did ACS1 or
ACS5. If these isoenzymes compete for the same pool of ATP,
ACS4 might remain active during fasting or when cellular
energy levels are low. On the other hand, however, the subcel-
lular location of ACS4 and its increase after refeeding (31)
suggest that ACS activities are not simply dependent on sub-
strate availability.
Despite their striking homology, the three ACS isoforms
exhibited marked differences in their responses to heating and
amino acid-modifying reagents. ACS4 was the most sensitive
isoform when heated at 43 °C. ACS1 and ACS4 had broad pH
optima from pH 7.4 to pH 9.0, whereas the optimum for ACS5
was from pH 7.4 to pH 8.0. ACS4 was more severely inhibited
by phenylglyoxal than were ACS1 or ACS5, suggesting that
arginine residues may be more critical for ACS4 activity. The
marked inhibition of only ACS4 by NEM suggests that sulfhy-
dryl group-containing amino acids may also be important. On
the other hand, none of the isoforms was affected by m-amino-
phenylboronate, indicating that serine is not an essential res-
idue for catalysis. Taken as a whole, the responses to site-
specific inhibitors probably reflect the relative similarity of
ACS1 and ACS5 in amino acid sequence and the relative dis-
similarity of ACS4.
ACS inhibitors such as triacsin C or troglitazone differen-
tially affect metabolic end products of ACS-dependent path-
ways (16–19). Thus, we hypothesized that pathways using
acyl-CoA substrates might be initiated by distinct ACS iso-
forms and that the different degree of inhibition of TAG, phos-
pholipid, and CE synthesis, or fatty acid b-oxidation by ACS
inhibitors might result if each ACS isoform had a different
sensitivity to the two inhibitors. If this were true, ACS isoforms
could play a critical role in partitioning their products toward
specific pathways through independent regulation of each ACS
isoform. This hypothesis was supported by our data. The cur-
rent study using purified ACS isoenzymes demonstrates that
ACS isoforms can be distinguished by their sensitivity to ACS
inhibitors. Triacsin C had little effect on ACS5, but strongly
inhibited ACS1 and ACS4 activities in a dose-dependent man-
ner. Because studies with cultured cells show that triacsin C
strongly blocks de novo synthesis of TAG and has little affect on
phospholipid reacylation or CE synthesis, or on b-oxidation
(16–18), ACS1 and ACS4 may be closely linked to TAG
synthesis.
Troglitazone at 10 mM did not alter ACS1 activity, mildly
inhibited ACS5 activity, and almost completely blocked ACS4
activity. a-Tocopherol was not an inhibitor, whereas rosiglita-
zone and pioglitazone were potent ACS4-specific inhibitors and
had little affect on ACS1 or ACS5. Thus, the critical component
for ACS4 inhibition appears to be the thiazolidine-2,4-dione
moiety rather than the a-tocopherol ring. It is most likely that
ACS4 inhibition by thiazolidinediones is more closely related to
TAG synthesis rather than to b-oxidation for several reasons.
1) ACS4 protein was most prominently located in the mitochon-
drial-associated membrane (31), which exhibits the highest
specific activities for enzymes of TAG synthesis (32), and was
not detected in mitochondria (31). 2) After a 48-h fast followed
by 24-h refeeding with chow or sucrose (69%), hepatic ACS4
protein increased 150% (31). 3) The preference of ACS4 for
arachidonic acids is consistent with only a weak link to b-oxi-
dation because arachidonic acid is among the least preferred
TABLE II
Effect of PPARg and PPARa activators and of selected xenobiotic
carboxylic acids on purified ACS1-, ACS4-, and ACS5-Flag activities
Purified ACS1-Flag and ACS4-Flag (each at 0.1 mg of protein) and 0.5
mg of ACS5-Flag were assayed for ACS activity in the presence of up to
50 mM test compound. Chemicals were dissolved in Me2SO, and the
amount of Me2SO was consistently maintained as 2.5% of the total






Troglitazone 1.5 NE NE
Pioglitazone 1.5 NE NE
Rosiglitazone 0.5 NE NE
GW1929 .50 50 NE
GW4647 NE NE NE




3-Phenoxybenzoate NE NE NE
p-Coumaric acid NE NE NE
Ferulic acid NE NE NE
Ibuprofen NE NE NE
Firefly luciferin NE NE NE
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fatty acids for b-oxidation during fasting states (33).
Thiazolidinediones appear to be highly specific inhibitors of
ACS4. Troglitazone exhibited mixed-type inhibition of ACS4 with
respect to all three substrates. Troglitazone is believed to activate
PPARg because it mimics a fatty acid; therefore, we postulated
that troglitazone might compete with palmitate in the acyl-CoA
ligation reaction. We found that troglitazone displayed linear
mixed-type inhibition (Fig. 5A). This could arise because the
ACS4-troglitazone complex has a lower affinity than ACS4 for
palmitate and the enzyme-substrate(s)-inhibitor complex is non-
productive. Another possibility is that troglitazone interacts
at more than one site, so we examined troglitazone inhibition
kinetics of ACS4 with CoA and ATP. Troglitazone is a partial
uncompetitive inhibitor of ACS4 with respect to CoA (Fig. 5C),
indicating that the affinity for CoA of the ACS4-troglitazone
complex increases by the same degree as the inhibitor decreases
vmax. For ATP, troglitazone displayed linear mixed-type inhibi-
tion with the reciprocal plots intersecting below the 1/palmitate
axis (Fig. 5D), suggesting that the ACS4-troglitazone complex
has an increased affinity for ATP, but that the enzyme-
substrate(s)-inhibitor complex forms product more slowly than
the enzyme-substrate(s) complex. It should be noted that these
types of inhibition kinetic systems were initially characterized
using soluble single substrate enzymes (30), whereas we are
extrapolating them to apply to a membrane-bound enzyme,
ACS4, that has three substrates, only two of which are soluble.
GW1929, a potent non-thiazolidinedione PPARg activator,
was a weak inhibitor of both ACS1 and ACS4, with an IC50
value for ACS4 more than 30-fold higher than that observed
with thiazolidinediones. ACS4 was not affected by the PPARa
activators clofibric acid and GW4647 at concentrations up to 50
FIG. 6. N-Ethylmaleimide inhibits ACS4. The reaction was initi-
ated by adding ACS1-Flag (E), ACS4-Flag (l) (each 0.1 mg), and ACS5-
Flag (f) (1 mg) that had been incubated with different concentrations of
NEM for 10 min on ice. The proteins were preincubated with NEM
dissolved in 10 mM Tris, and 0.5 mM EDTA (pH 7.4) buffer. The values
are from an experiment that is representative of two independent
determinations. Uninhibited activities were 1159 for ACS1, 2477 for
ACS4, and 113 nmol/min/mg for ACS5.
FIG. 5. Troglitazone is a mixed-type inhibitor of ACS4. Purified ACS4-Flag (0.1 mg) was assayed for ACS activity for 1 min at 37 °C.
Troglitazone was dissolved in Me2SO (DMSO; 2.5% of final assay reaction). A, Lineweaver-Burk plot with palmitate; B, replots of Km/vmax and
1/vmax versus troglitazone; C, Lineweaver-Burk plot with CoA; D, Lineweaver-Burk plot with ATP.
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mM, even though these compounds, like the thiazolidinediones,
can markedly lower hyperinsulinemia and hyperglycemia in
diabetic animal models (28). Furthermore, ACS4 was unaf-
fected by a variety of xenobiotic carboxylic acids that contain
hydrophobic rings and are known to be incorporated into com-
plex lipids.
Although we did not test the effects of troglitazone O-sulfate
(TOS), a major troglitazone metabolite, 100 mM TOS was re-
ported to inhibit ACS activity 80% in both microsomes and
mitochondria from rat hepatocytes, whereas troglitazone itself
had no effect (19). The purity of the membrane fractions used in
the reported study was not evaluated. We found that troglita-
zone at 10 and 50 mM inhibited ACS activity 25% and 50%,
respectively, in purified mitochondria-associated membrane
fractions (31). The reported poor ability of troglitazone to in-
hibit ACS activity (19) probably occurred because the mem-
brane fractions used in that study contained relatively little
ACS4, but may have contained other ACS isoforms that were
sensitive to high concentrations of TOS or to an inhibitory
factor elicited by TOS.
Thiazolidinediones are powerful oral antidiabetic drugs that
act as insulin sensitizers. Although it is believed that their
efficacy occurs via activation of PPARg (24–26), some evidence
suggests that some thiazolidinedione actions can occur in a
PPARg-independent manner. In PPARg-deficient heterozygous
mice, for example, glucose disposal rate and suppression of
hepatic glucose production are greater than in normal mice, the
reverse of what one would expect if thiazolidinediones amelio-
rate insulin resistance by activating PPARg (34). Further,
some compounds exhibit potent antidiabetic effects despite
their weak activation of PPARg (35). Troglitazone and rosigli-
tazone decrease serum triacylglycerol even in aP2/DTA mice,
which lack adipose deposits, a main site for PPARg action
(36–38); troglitazone has acute effects in rats both on glucose
disposal and on hepatic glucose production (39); finally, TZDs
can decrease the expression of tumor necrosis factor-a and
interleukin-6 in macrophages that contain no PPARg (40). Our
results suggest that ACS4 could contribute to the insulin-
sensitizing and anti-inflammatory effects of the thiazo-
lidinediones through direct interaction with ACS4 in a PPARg-
independent manner.
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